$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino

$ino Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-K Financial Statement

#000105572614000003 Filed on March 17, 2014

Income Statement

Concept	2012 Q4	2012 Q3	2012 Q2
Revenue	$1.135M	$854.7K	$436.1K
YoY Change	-30.5%	-67.6%	-81.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.920M	$2.060M	$2.070M
YoY Change	-10.15%	-11.21%	-33.01%
% of Gross Profit
Research & Development	$4.443M	$4.972M	$4.527M
YoY Change	6.84%	-28.84%	1.41%
% of Gross Profit
Depreciation & Amortization	$500.0K	$490.0K	$500.0K
YoY Change	0.0%	-2.0%	-1.96%
% of Gross Profit
Operating Expenses	$7.362M	$7.147M	$7.224M
YoY Change	-0.68%	-20.36%	-4.4%
Operating Profit	-$6.227M	-$6.292M	-$6.788M
YoY Change	7.74%	-0.7%	32.15%
Interest Expense	$5.560M	-$340.0K	$2.640M
YoY Change	1817.24%	-119.1%	14.78%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$670.0K	-$6.630M	-$4.140M
YoY Change	-87.8%	45.39%	45.77%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$658.8K	-$6.622M	-$4.133M
YoY Change	-87.97%	45.8%	46.45%
Net Earnings / Revenue	-58.05%	-774.79%	-947.8%
Basic Earnings Per Share
Diluted Earnings Per Share	-$18.76K	-$195.6K	-$122.4K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q4	2012 Q3	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.70M	$15.10M	$19.40M
YoY Change	-54.64%	-51.45%	-46.7%
Cash & Equivalents	$5.646M	$4.589M	$5.952M
Short-Term Investments	$8.000M	$10.60M	$13.50M
Other Short-Term Assets	$1.500M	$1.200M	$1.400M
YoY Change	25.0%	0.0%	-22.22%
Inventory
Prepaid Expenses
Receivables	$830.4K	$500.0K	$400.0K
Other Receivables	$100.0K	$100.0K	$100.0K
Total Short-Term Assets	$15.97M	$16.90M	$21.30M
YoY Change	-49.95%	-48.32%	-44.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$363.0K	$400.0K	$400.0K
YoY Change	22.73%	33.33%	33.33%
Goodwill	$10.11M
YoY Change	0.0%
Intangibles	$7.489M
YoY Change	-19.56%
Long-Term Investments	$10.70M	$8.300M	$7.500M
YoY Change	17.58%	-16.16%	-10.71%
Other Assets	$134.2K	$800.0K	$800.0K
YoY Change	-35.57%	100.0%	300.0%
Total Long-Term Assets	$29.17M	$27.60M	$27.30M
YoY Change	-0.1%	-9.8%	-6.83%
TOTAL ASSETS
Total Short-Term Assets	$15.97M	$16.90M	$21.30M
Total Long-Term Assets	$29.17M	$27.60M	$27.30M
Total Assets	$45.14M	$44.50M	$48.60M
YoY Change	-26.13%	-29.7%	-28.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.400M	$3.200M	$3.600M
YoY Change	-20.93%	-17.95%	-10.0%
Accrued Expenses	$1.406M	$1.400M	$1.200M
YoY Change	32.71%	75.0%	200.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.377M	$11.30M	$10.20M
YoY Change	-24.15%	16.49%	3.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.700M	$1.800M	$1.900M
YoY Change	-19.05%	-18.18%	-17.39%
Total Long-Term Liabilities	$1.700M	$1.800M	$1.900M
YoY Change	-19.05%	-18.18%	-17.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.377M	$11.30M	$10.20M
Total Long-Term Liabilities	$1.700M	$1.800M	$1.900M
Total Liabilities	$10.28M	$13.70M	$12.80M
YoY Change	-22.38%	9.6%	0.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$229.8M
YoY Change	9.36%
Common Stock	$144.3K
YoY Change	6.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$34.35M	$30.80M	$35.80M
YoY Change
Total Liabilities & Shareholders Equity	$45.14M	$44.50M	$48.60M
YoY Change	-26.13%	-29.7%	-28.42%

Cashflow Statement

Concept	2012 Q4	2012 Q3	2012 Q2
OPERATING ACTIVITIES
Net Income	-$658.8K	-$6.622M	-$4.133M
YoY Change	-87.97%	45.8%	46.45%
Depreciation, Depletion And Amortization	$500.0K	$490.0K	$500.0K
YoY Change	0.0%	-2.0%	-1.96%
Cash From Operating Activities	-$5.530M	-$6.030M	-$5.310M
YoY Change	21.81%	14.64%	19.06%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$20.00K	-$100.0K
YoY Change	-60.0%	100.0%	150.0%
Acquisitions
YoY Change
Other Investing Activities	$2.500M	$3.460M	$250.0K
YoY Change	-135.41%		-111.9%
Cash From Investing Activities	$2.480M	$3.450M	$130.0K
YoY Change	-134.88%	-17350.0%	-106.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.100M	1.230M	0.000
YoY Change	11.11%
NET CHANGE
Cash From Operating Activities	-5.530M	-6.030M	-5.310M
Cash From Investing Activities	2.480M	3.450M	130.0K
Cash From Financing Activities	4.100M	1.230M	0.000
Net Change In Cash	1.050M	-1.350M	-5.180M
YoY Change	-113.19%	-74.43%	-21.4%
FREE CASH FLOW
Cash From Operating Activities	-$5.530M	-$6.030M	-$5.310M
Capital Expenditures	-$20.00K	-$20.00K	-$100.0K
Free Cash Flow	-$5.510M	-$6.010M	-$5.210M
YoY Change	22.72%	14.48%	17.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-76365	USD
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3181574	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5444508	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	5444508	USD
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	3181574	USD
CY2012Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	852573	USD
CY2013Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	1865723	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3301563	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	830433	USD
CY2013Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	0	USD
CY2012Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	36234	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1446180	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1405896	USD
CY2013Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2586806	USD
CY2012Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1560704	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1915428	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2117702	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	73362	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	348109661	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	263897116	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1821170	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1770537	USD
CY2011	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1869517	USD
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36084880	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30635611	shares
CY2013Q4	us-gaap	Available For Sale Securities Equity Securities Noncurrent AvailableForSaleSecuritiesEquitySecuritiesNoncurrent	717500	USD
CY2012Q4	us-gaap	Available For Sale Securities Equity Securities Noncurrent AvailableForSaleSecuritiesEquitySecuritiesNoncurrent	267200	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	18983662	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	7951533	USD
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	37889521	shares
CY2013Q4	us-gaap	Assets Assets	88287207	USD
CY2012Q4	us-gaap	Assets Assets	45138754	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	58683589	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	15967912	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	18905608	USD
CY2012Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	8034001	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5646021	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33719796	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19998489	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17350116	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	28073775	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-11704095	USD
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2648373	USD
CY2011Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	1.40
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14059260	shares
CY2012Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21593844	shares
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	210304821	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	144313005	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	210304821	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	144313005	shares
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	144313	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	210305	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66233259	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19675011	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15271552	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-55084	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-44025	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-51150	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-66178175	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-15220402	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-19630986	USD
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents, and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. The Company had contracts with customers which represented more than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10%</font><font style="font-family:inherit;font-size:10pt;"> of total revenues for all of the years presented as discussed in Note 6.</font></div></div>
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7000	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-1000	USD
CY2011	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-1000	USD
CY2011	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000	USD
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	15000	USD
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	20000	USD
CY2011	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	19000	USD
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	23000	USD
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	26000	USD
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	32000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	65076	USD
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3013263	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1624388	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	353391	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1997333	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	88609	USD
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	17000	USD
CY2011	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	7000	USD
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	3000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	62146000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	54127000	USD
CY2012Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3191000	USD
CY2013Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2782000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1085000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1942000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	62728	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	61839	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	48846000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	43233000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	8641000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6569000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	1134000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	1877000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52185000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61061000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	134000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	101000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1096000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1532000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	123000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	511000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	164393	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	195778	USD
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	170000	USD
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	196000	USD
CY2011	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	134000	USD
CY2013	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2013	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.5
CY2013	us-gaap	Depreciation Depreciation	328752	USD
CY2012	us-gaap	Depreciation Depreciation	173750	USD
CY2011	us-gaap	Depreciation Depreciation	142197	USD
CY2012Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	187275	USD
CY2013Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	522255	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.00
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2013	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	118	USD
CY2012	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1984	USD
CY2011	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-3263	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2012Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	944000	USD
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	956000	USD
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M0D
CY2012	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
CY2013	us-gaap	Fair Value Assumptions Expected Dividend Payments FairValueAssumptionsExpectedDividendPayments	0
CY2012	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-2316420	USD
CY2011	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-8827658	USD
CY2013	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	46082969	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12128558	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13899095	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1542000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	943000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	773000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	775000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	816000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	870000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19617873	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19617873	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5718778	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7489315	USD
CY2013	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	2000000	USD
CY2011	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	587000	USD
CY2012	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1151000	USD
CY2013Q2	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	USD
CY2013Q3	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
CY2013Q4	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	USD
CY2013Q1	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
CY2012Q3	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	500000	USD
CY2012Q2	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
CY2012Q1	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	651000	USD
CY2012Q4	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
CY2012	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2011	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2013	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1822	USD
CY2013	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	501000	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11988796	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10778359	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13643074	USD
CY2013Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4339539	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3046586	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2974153	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3282796	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2696909	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2488088	USD
CY2012Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2919000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2674362	USD
CY2012Q4	us-gaap	Goodwill Goodwill	10113371	USD
CY2013Q4	us-gaap	Goodwill Goodwill	10113371	USD
CY2012Q4	us-gaap	Goodwill Gross GoodwillGross	10113371	USD
CY2013Q4	us-gaap	Goodwill Gross GoodwillGross	10113371	USD
CY2013	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2011	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2012	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-479000	USD
CY2011	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1272000	USD
CY2012	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	495000	USD
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1234000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31000	USD
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	27000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8819000	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7415000	USD
CY2011	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7679000	USD
CY2011	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	125000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-623000	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	438000	USD
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6894000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-23118000	USD
CY2011	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5352000	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	279000	USD
CY2011	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-147000	USD
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	603000	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1651000	USD
CY2011	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1378000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2164045	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-790844	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1789376	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	334980	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-1660603	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	166931	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2471130	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	362524	USD
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	435022	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-36234	USD
CY2011	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-33743	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-2172	USD
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-333725	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	282048	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3179721	USD
CY2011	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-50866	USD
CY2013	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-26793	USD
CY2012	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	14794	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	472074	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	229705	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-363584	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	352	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	351	USD
CY2011	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	100059	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5718778	USD
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7489315	USD
CY2011	us-gaap	Interest And Other Income InterestAndOtherIncome	34285	USD
CY2012	us-gaap	Interest And Other Income InterestAndOtherIncome	166113	USD
CY2013	us-gaap	Interest And Other Income InterestAndOtherIncome	132214	USD
CY2013Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	39460	USD
CY2013Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	46787	USD
CY2013Q4	us-gaap	Interest And Other Income InterestAndOtherIncome	8576	USD
CY2013Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	37391	USD
CY2012Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	41036	USD
CY2012Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	31544	USD
CY2012Q4	us-gaap	Interest And Other Income InterestAndOtherIncome	56520	USD
CY2012Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	37013	USD
CY2012Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	10703332	USD
CY2013Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	9664587	USD
CY2011Q4	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	0	USD
CY2012Q4	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	0	USD
CY2013Q4	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	2538000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	35384524	USD
CY2012Q4	us-gaap	Liabilities Liabilities	10281349	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	88287207	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45138754	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8376577	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28966456	USD
CY2012Q4	us-gaap	Minority Interest MinorityInterest	502743	USD
CY2013Q4	us-gaap	Minority Interest MinorityInterest	447659	USD
CY2013Q4	us-gaap	Minority Interest Ownership Percentage By Noncontrolling Owners MinorityInterestOwnershipPercentageByNoncontrollingOwners	0.09
CY2012Q4	us-gaap	Minority Interest Ownership Percentage By Noncontrolling Owners MinorityInterestOwnershipPercentageByNoncontrollingOwners	0.09
CY2013Q4	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.88
CY2013	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio Pharmaceuticals, Inc. (the “Company” or “Inovio”) is developing vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. The Company's DNA-based immune therapies, in combination with its proprietary electroporation delivery devices, are generating immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. In addition, the Company's novel SynCon</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> vaccine design has shown the ability to help break the immune system’s tolerance of cancerous cells. Given the recognized role of killer T cells in eliminating cancerous or infected cells from the body, Inovio’s scientists believe that its active immunotherapies may play an important role in helping fight these diseases. Inovio's SynCon</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> design is also intended to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. Human data to date have shown a favorable safety profile of the Company's DNA vaccines delivered using electroporation. The Company has completed, current or planned clinical programs of its proprietary SynCon</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> vaccines and immunotherapies for HPV-caused pre-cancers and cancers (therapeutic), influenza (preventive), prostate cancer (therapeutic), breast/lung/pancreatic cancer (therapeutic), hepatitis C virus (HCV) (therapeutic), hepatitis B virus (HBV) (therapeutic), HIV, and malaria (preventive and therapeutic). The Company's partners and collaborators include Roche, University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (“PATH”/ “MVI”), National Institute of Allergy and Infectious Diseases (“NIAID”), Merck, United States Military HIV Research Program (“USMHRP”), U.S. Army Medical Research Institute of Infectious Diseases (“USAMRIID”), HIV Vaccines Trial Network (“HVTN”) and Department of Homeland Security (“DHS”).</font></div></div>
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28010531	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5325141	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52691937	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9236843	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5275565	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10899924	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15381437	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22306785	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19755717	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-66028448	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-19668955	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-15252945	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-30877410	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-10852588	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-8844120	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-15454330	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-6622076	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-8254949	USD
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-658751	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-4133179	USD
CY2012	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-44025	USD
CY2013	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-55084	USD
CY2011	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-51150	USD
CY2013Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13443	USD
CY2013Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14160	USD
CY2013Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13473	USD
CY2013Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14008	USD
CY2012Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12553	USD
CY2012Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10413	USD
CY2012Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-11289	USD
CY2012Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9770	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	27612184	USD
CY2011	us-gaap	Operating Expenses OperatingExpenses	31433797	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	33011678	USD
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	9743544	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	8721201	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	6457668	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	8089265	USD
CY2012Q4	us-gaap	Operating Expenses OperatingExpenses	7361841	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	7223995	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	7146681	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	5879667	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-23493532	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-21638540	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-19544332	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6634040	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	765644	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5672058	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-8003878	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4186546	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6787913	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6291985	USD
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-6227088	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	7754000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	233000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	668000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	739000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	817000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	677000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	4620000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	906000	USD
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	430000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	444000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	768297	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	991979	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	402075	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	134193	USD
CY2012	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1984	USD
CY2013	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	118	USD
CY2011	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3263	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-149845	USD
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	35985	USD
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	35806	USD
CY2013	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	39000	USD
CY2012	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	0	USD
CY2011	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	0	USD
CY2012	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
CY2013	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
CY2011	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	101123	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	161187	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	240986	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	176925	USD
CY2013	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	15399495	USD
CY2012	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	9142220	USD
CY2011	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	18193614	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	26	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	26	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	26	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	26	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	471328	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	637433	USD
CY2013	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassification</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to the prior year consolidated financial statements to conform to the current year presentation.</font></div></div>
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5325141	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32883705	USD
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27994601	USD
CY2012	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	650000	USD
CY2011	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	350000	USD
CY2013	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	2000000	USD
CY2012	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	14008771	USD
CY2013	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	4339577	USD
CY2011	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	7206000	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1600000	USD
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16000	USD
CY2012	us-gaap	Profit Loss ProfitLoss	-19712980	USD
CY2011	us-gaap	Profit Loss ProfitLoss	-15304095	USD
CY2013	us-gaap	Profit Loss ProfitLoss	-66083532	USD
CY2013Q1	us-gaap	Profit Loss ProfitLoss	-8858280	USD
CY2013Q4	us-gaap	Profit Loss ProfitLoss	-15467803	USD
CY2013Q3	us-gaap	Profit Loss ProfitLoss	-30890853	USD
CY2013Q2	us-gaap	Profit Loss ProfitLoss	-10866596	USD
CY2012Q3	us-gaap	Profit Loss ProfitLoss	-6632489	USD
CY2012Q2	us-gaap	Profit Loss ProfitLoss	-4144468	USD
CY2012Q4	us-gaap	Profit Loss ProfitLoss	-671304	USD
CY2012Q1	us-gaap	Profit Loss ProfitLoss	-8264719	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2480723	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4801973	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	363021	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2886545	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17984825	USD
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20032001	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21368604	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4411082	USD
CY2013Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6404005	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5438405	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5115112	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4527086	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4972319	USD
CY2012Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4442841	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4042579	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100410	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100762	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-229760129	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-295788577	USD
CY2013	us-gaap	Revenue From Grants RevenueFromGrants	3802799	USD
CY2012	us-gaap	Revenue From Grants RevenueFromGrants	3458649	USD
CY2011	us-gaap	Revenue From Grants RevenueFromGrants	9227401	USD
CY2013Q2	us-gaap	Revenue From Grants RevenueFromGrants	665049	USD
CY2013Q4	us-gaap	Revenue From Grants RevenueFromGrants	811199	USD
CY2013Q3	us-gaap	Revenue From Grants RevenueFromGrants	991835	USD
CY2013Q1	us-gaap	Revenue From Grants RevenueFromGrants	1334716	USD
CY2012Q1	us-gaap	Revenue From Grants RevenueFromGrants	1562033	USD
CY2012Q3	us-gaap	Revenue From Grants RevenueFromGrants	609717	USD
CY2012Q2	us-gaap	Revenue From Grants RevenueFromGrants	308925	USD
CY2012Q4	us-gaap	Revenue From Grants RevenueFromGrants	977974	USD
CY2013	us-gaap	Revenues Revenues	13467346	USD
CY2012	us-gaap	Revenues Revenues	4118652	USD
CY2011	us-gaap	Revenues Revenues	9795257	USD
CY2013Q2	us-gaap	Revenues Revenues	785610	USD
CY2013Q3	us-gaap	Revenues Revenues	9486845	USD
CY2013Q1	us-gaap	Revenues Revenues	1455225	USD
CY2013Q4	us-gaap	Revenues Revenues	1739666	USD
CY2012Q2	us-gaap	Revenues Revenues	436082	USD
CY2012Q1	us-gaap	Revenues Revenues	1693121	USD
CY2012Q3	us-gaap	Revenues Revenues	854696	USD
CY2012Q4	us-gaap	Revenues Revenues	1134753	USD
CY2011	us-gaap	Sales Revenue Net SalesRevenueNet	9795257	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	13467346	USD
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	4118652	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	1868345	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	1654823	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	1345613	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	65000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2500000	USD
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	100000	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	207498	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	496012	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	779109	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	707737	shares
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	347606	shares
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.25
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.30
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.55
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2913625	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2733750	shares
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2068750	shares
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.90
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.44
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.47
CY2009Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12649968	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16538118	shares
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14302803	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16257444	shares
CY2009Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.49
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.42
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.21
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.28
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.81
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.23
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.08
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.33
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.83
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.61
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.58
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.10
CY2013Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	12690114	shares
CY2013Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	16538118	shares
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	20100000	USD
CY2013Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	1.38
CY2013Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	1.21
CY2013	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y6M12D
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	8034001	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	18905608	USD
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1925214	shares
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2011	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	68309	shares
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5325141	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	18924856	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1351669	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1868345	USD
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1345613	USD
CY2011	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1654823	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	52455024	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	34354662	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34857405	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	52902683	USD
CY2010Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	47100911	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	47861662	USD
CY2011	us-gaap	Straight Line Rent StraightLineRent	-13763	USD
CY2012	us-gaap	Straight Line Rent StraightLineRent	15799	USD
CY2013	us-gaap	Straight Line Rent StraightLineRent	-410187	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1829000	USD
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	629000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2416000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1896000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	72000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	305000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	158000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	-5000	USD
CY2013Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	19540583	USD
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	136509247	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	184351090	shares
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1042000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	215000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2000000	USD
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	126239336	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	156155532	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	191956155	shares
CY2013Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	208509676	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	179954816	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	134968394	shares
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	135389308	shares
CY2012Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	140704889	shares
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	134968394	shares
CY2013Q4	ino	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	560	USD
CY2012Q4	ino	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	83868	USD
CY2013Q4	ino	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	78614	USD
CY2012Q4	ino	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	1400	USD
CY2013	ino	Cashless Exerciseof Warrants Value CashlessExerciseofWarrantsValue	0	USD
CY2012	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	1982620	USD
CY2011	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	8690658	USD
CY2013	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-45632669	USD
CY2013Q1	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-1427616	USD
CY2013Q2	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-3199878	USD
CY2013Q4	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-6052965	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in accordance with United States generally accepted accounting principles requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Inovio bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, the Company reviews its estimates to ensure that these estimates appropriately reflect changes in the business or as new information becomes available.</font></div></div>
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2859899	USD
CY2013Q3	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-34952210	USD
CY2012Q3	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-1113638	USD
CY2012Q2	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	3594782	USD
CY2012Q1	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-3548173	USD
CY2012Q4	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	3049649	USD
CY2011	ino	Change In Value Of Common Stock Warrants ChangeInValueOfCommonStockWarrants	-8690658	USD
CY2013	ino	Change In Value Of Common Stock Warrants ChangeInValueOfCommonStockWarrants	45632669	USD
CY2012	ino	Change In Value Of Common Stock Warrants ChangeInValueOfCommonStockWarrants	-1982620	USD
CY2011	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-2390498	USD
CY2013	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-1038745	USD
CY2012	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	1631819	USD
CY2013Q1	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-836084	USD
CY2013	ino	Income Tax Reconciliation Fair Value Warrant IncomeTaxReconciliationFairValueWarrant	16129000	USD
CY2012	ino	Income Tax Reconciliation Fair Value Warrant IncomeTaxReconciliationFairValueWarrant	-811000	USD
CY2011	ino	Income Tax Reconciliation Statute Limitations IncomeTaxReconciliationStatuteLimitations	918000	USD
CY2012Q4	ino	Goodwill And Intangible Assets Gross GoodwillAndIntangibleAssetsGross	29731244	USD
CY2013Q4	ino	Goodwill And Intangible Assets Gross GoodwillAndIntangibleAssetsGross	29731244	USD
CY2012Q4	ino	Goodwill And Intangible Assets Net GoodwillAndIntangibleAssetsNet	17602686	USD
CY2013	ino	Recognition Amortization Of Deferred Tax Liabilities RecognitionAmortizationOfDeferredTaxLiabilities	32274	USD
CY2013Q4	ino	Goodwill And Intangible Assets Net GoodwillAndIntangibleAssetsNet	15832149	USD
CY2013	ino	Impairment Of Long Term Investments ImpairmentOfLongTermInvestments	38950	USD
CY2011	ino	Impairment Of Long Term Investments ImpairmentOfLongTermInvestments	0	USD
CY2012	ino	Impairment Of Long Term Investments ImpairmentOfLongTermInvestments	0	USD
CY2011	ino	Income Tax Reconciliation Fair Value Warrant IncomeTaxReconciliationFairValueWarrant	-3090000	USD
CY2013	ino	Issuance Of Common Stock For Cash Financing Costs IssuanceOfCommonStockForCashFinancingCosts	585000	USD
CY2013Q4	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-1419536	USD
CY2013Q2	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-2032051	USD
CY2013Q3	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	3248926	USD
CY2012Q2	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-992373	USD
CY2012Q3	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	736121	USD
CY2012Q4	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	2449615	USD
CY2012Q1	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-561544	USD
CY2013	ino	Changein Classificationof Warrantsfrom Liabilityto Equity Dueto Exercise ChangeinClassificationofWarrantsfromLiabilitytoEquityDuetoExercise	35370529	USD
CY2013Q4	ino	Classof Warrantor Right Numberof Warrants Exercised ClassofWarrantorRightNumberofWarrantsExercised	3870200	shares
CY2013	ino	Convertible Preferred Stock Shares Issued Upon Conversion Conversion Price Per Share ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare	6.80
CY2012Q4	ino	Deferred Revenue From Affiliated Entity Current DeferredRevenueFromAffiliatedEntityCurrent	388542	USD
CY2013Q4	ino	Deferred Revenue From Affiliated Entity Current DeferredRevenueFromAffiliatedEntityCurrent	388542	USD
CY2012Q4	ino	Deferred Revenue From Affiliated Entity Noncurrent DeferredRevenueFromAffiliatedEntityNoncurrent	1586694	USD
CY2013Q4	ino	Deferred Revenue From Affiliated Entity Noncurrent DeferredRevenueFromAffiliatedEntityNoncurrent	1211694	USD
CY2013	ino	Exercise Of Stock Options And Warrants For Cash ExerciseOfStockOptionsAndWarrantsForCash	19808232	USD
CY2011	ino	Exercise Of Stock Options And Warrants For Cash ExerciseOfStockOptionsAndWarrantsForCash	15930	USD
CY2011	ino	Fair Value Of Common Stock Warrants Issued In Connection With Equity Financing FairValueOfCommonStockWarrantsIssuedInConnectionWithEquityFinancing	-11727372	USD
CY2013	ino	Fair Value Of Common Stock Warrants Issued In Connection With Equity Financing FairValueOfCommonStockWarrantsIssuedInConnectionWithEquityFinancing	-5968244	USD
CY2013	ino	Income Tax Reconciliation Statute Limitations IncomeTaxReconciliationStatuteLimitations	675000	USD
CY2012	ino	Income Tax Reconciliation Statute Limitations IncomeTaxReconciliationStatuteLimitations	18000	USD
CY2013	ino	Increase Decrease In Deferred Revenue From Related Parties IncreaseDecreaseInDeferredRevenueFromRelatedParties	-375000	USD
CY2012	ino	Increase Decrease In Deferred Revenue From Related Parties IncreaseDecreaseInDeferredRevenueFromRelatedParties	-375000	USD
CY2011	ino	Increase Decrease In Deferred Revenue From Related Parties IncreaseDecreaseInDeferredRevenueFromRelatedParties	-361458	USD
CY2012	ino	Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	445981	USD
CY2011	ino	Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	-212250	USD
CY2013	ino	Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	1401258	USD
CY2013	ino	Interest Income Accrued On Short Term Investments Certificates Of Deposit InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit	-484	USD
CY2011	ino	Interest Income Accrued On Short Term Investments Certificates Of Deposit InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit	6271	USD
CY2012	ino	Interest Income Accrued On Short Term Investments Certificates Of Deposit InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit	-1147	USD
CY2011	ino	Issuance Of Common Stock And Warrants For Cash Financing Costs IssuanceOfCommonStockAndWarrantsForCashFinancingCosts	1300000	USD
CY2013	ino	Issuance Of Common Stock And Warrants For Cash Financing Costs IssuanceOfCommonStockAndWarrantsForCashFinancingCosts	783000	USD
CY2013	ino	Issuance Of Common Stock And Warrants For Cash Net Of Financing Costs IssuanceOfCommonStockAndWarrantsForCashNetOfFinancingCosts	14274819	USD
CY2011	ino	Issuance Of Common Stock And Warrants For Cash Net Of Financing Costs IssuanceOfCommonStockAndWarrantsForCashNetOfFinancingCosts	22957803	USD
CY2011	ino	Issuance Of Common Stock For Cash Financing Costs IssuanceOfCommonStockForCashFinancingCosts	41838	USD
CY2012	ino	Issuance Of Common Stock For Cash Financing Costs IssuanceOfCommonStockForCashFinancingCosts	164695	USD
CY2013	ino	Preferred Stock Conversion Daily Market Price Triggering Mandatory Conversion PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion	18.00
CY2012Q4	ino	Prepaid Expenses And Other Current Assets From Affiliated Entity PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	887167	USD
CY2013Q4	ino	Prepaid Expenses And Other Current Assets From Affiliated Entity PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	2057350	USD
CY2013	ino	Proceedsfrom Stock Optionand Warrant Exercises ProceedsfromStockOptionandWarrantExercises	19808232	USD
CY2012	ino	Proceedsfrom Stock Optionand Warrant Exercises ProceedsfromStockOptionandWarrantExercises	0	USD
CY2011	ino	Proceedsfrom Stock Optionand Warrant Exercises ProceedsfromStockOptionandWarrantExercises	15930	USD
CY2012	ino	Recognition Amortization Of Deferred Tax Liabilities RecognitionAmortizationOfDeferredTaxLiabilities	22806	USD
CY2011	ino	Recognition Amortization Of Deferred Tax Liabilities RecognitionAmortizationOfDeferredTaxLiabilities	25673	USD
CY2012	ino	Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity	577467	USD
CY2011	ino	Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity	411459	USD
CY2013	ino	Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity	425000	USD
CY2012Q3	ino	Revenue Under Collaborative Researchand Development Arrangements RevenueUnderCollaborativeResearchandDevelopmentArrangements	22495	USD
CY2012Q1	ino	Revenue Under Collaborative Researchand Development Arrangements RevenueUnderCollaborativeResearchandDevelopmentArrangements	24838	USD
CY2013	ino	Share Based Compensation Arrangement By Share Based Payment Award Maximum Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm	P10Y
CY2013	ino	Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm	P4Y8M12D
CY2013	ino	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue	28700000	USD
CY2013Q4	ino	Sharebased Compensation Arrangementby Sharebased Payment Award Options Expectedto Vest Outstanding Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber	3540163	shares
CY2013Q4	ino	Tax Benefits Expired TaxBenefitsExpired	28300000	USD
CY2011	ino	Transaction Costs Associated With Issuanceof Warrants TransactionCostsAssociatedWithIssuanceofWarrants	0	USD
CY2012	ino	Transaction Costs Associated With Issuanceof Warrants TransactionCostsAssociatedWithIssuanceofWarrants	0	USD
CY2013	ino	Transaction Costs Associated With Issuanceof Warrants TransactionCostsAssociatedWithIssuanceofWarrants	315970	USD
CY2013Q4	ino	Warrants Received During Period WarrantsReceivedDuringPeriod	718000	USD
CY2012Q4	ino	Weighted Average Price Per Share On Sale Of Common Stock WeightedAveragePricePerShareOnSaleOfCommonStock	0.59
CY2013Q3	ino	Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity	106250	USD
CY2013Q1	ino	Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity	106250	USD
CY2013Q2	ino	Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity	106250	USD
CY2013Q4	ino	Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity	106250	USD
CY2012Q3	ino	Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity	222484	USD
CY2012Q2	ino	Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity	106250	USD
CY2012Q1	ino	Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity	106250	USD
CY2012Q4	ino	Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity	142483	USD
CY2012	ino	Revenue Under Collaborative Researchand Development Arrangements RevenueUnderCollaborativeResearchandDevelopmentArrangements	82536	USD
CY2013	ino	Revenue Under Collaborative Researchand Development Arrangements RevenueUnderCollaborativeResearchandDevelopmentArrangements	9239547	USD
CY2011	ino	Revenue Under Collaborative Researchand Development Arrangements RevenueUnderCollaborativeResearchandDevelopmentArrangements	156397	USD
CY2013Q1	ino	Revenue Under Collaborative Researchand Development Arrangements RevenueUnderCollaborativeResearchandDevelopmentArrangements	14259	USD
CY2013Q4	ino	Revenue Under Collaborative Researchand Development Arrangements RevenueUnderCollaborativeResearchandDevelopmentArrangements	822217	USD
CY2013Q2	ino	Revenue Under Collaborative Researchand Development Arrangements RevenueUnderCollaborativeResearchandDevelopmentArrangements	14311	USD
CY2013Q3	ino	Revenue Under Collaborative Researchand Development Arrangements RevenueUnderCollaborativeResearchandDevelopmentArrangements	8388760	USD
CY2012Q2	ino	Revenue Under Collaborative Researchand Development Arrangements RevenueUnderCollaborativeResearchandDevelopmentArrangements	20907	USD
CY2012Q4	ino	Revenue Under Collaborative Researchand Development Arrangements RevenueUnderCollaborativeResearchandDevelopmentArrangements	14296	USD
CY2013Q4	ino	Weighted Average Price Per Share On Sale Of Common Stock WeightedAveragePricePerShareOnSaleOfCommonStock	1.24
CY2013Q4	ino	Working Capital WorkingCapital	29700000	USD
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001055726
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	239609760	shares
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q2	dei	Entity Public Float EntityPublicFloat	133199615	USD
CY2013	dei	Entity Registrant Name EntityRegistrantName	INOVIO PHARMACEUTICALS, INC.
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No

Files In Submission

Name	View Source	Status
0001055726-14-000003-index-headers.html	Edgar Link	pending
0001055726-14-000003-index.html	Edgar Link	pending
0001055726-14-000003.txt	Edgar Link	pending
0001055726-14-000003-xbrl.zip	Edgar Link	pending
exhibit.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ino-12312013x10k.htm	Edgar Link	pending
ino-12312013x10kex1036.htm	Edgar Link	pending
ino-12312013x10kex211.htm	Edgar Link	pending
ino-12312013x10kex231.htm	Edgar Link	pending
ino-12312013x10kex311.htm	Edgar Link	pending
ino-12312013x10kex312.htm	Edgar Link	pending
ino-12312013x10kex321.htm	Edgar Link	pending
ino-20131231.xml	Edgar Link	completed
ino-20131231.xsd	Edgar Link	pending
ino-20131231_cal.xml	Edgar Link	unprocessable
ino-20131231_def.xml	Edgar Link	unprocessable
ino-20131231_lab.xml	Edgar Link	unprocessable
ino-20131231_pre.xml	Edgar Link	unprocessable
inoviograph2013.jpg	Edgar Link	pending
inoviolease022414fina_image2.jpg	Edgar Link	pending
inoviolease022414fina_image3.jpg	Edgar Link	pending
inoviolease022414fina_image4.jpg	Edgar Link	pending
inoviolease022414fina_image5.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino

2012 Q4 Form 10-K Financial Statement

#000105572614000003 Filed on March 17, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INO INOVIO PHARMACEUTICALS, INC. Stock $ino

2012 Q4 Form 10-K Financial Statement

#000105572614000003 Filed on March 17, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino